Vertex Pharmaceuticals Incorporated's results for Q3 2026 (ended Sep 30, 2026) come from the company's own earnings release, filed with the SEC on 2026-11-02. Everything below is taken from that filing; quotes are copied exactly. Company outlooks are the company's own.
At a glance
| Item | Value |
|---|---|
| Revenue (GAAP total revenues) | $3,441 million (+11.8% vs a year earlier) |
| Diluted EPS (GAAP) | $2.56 |
| Adjusted per-share figure (company's non-GAAP measure; FFO/AFFO for REITs) | $4.76 |
| Full-year guidance | Raised |
Guidance
Vertex raised 2026 revenue guidance to $13.15–13.25 billion from $13.1–13.2 billion and increased operating expense guidance for the Crinetics acquisition.
Why this label: 'raised its full year 2026 total revenue guidance' to $13.15-13.25B from $13.1-13.2B; higher opex guide is non-core; no EPS guide.
| Metric | Period | New | Prior (as stated in the release) |
|---|---|---|---|
| total revenue | FY2026 | $13.15–13.25 billion | $13.1–13.2 billion |
| PALSONIFY revenue | FY2026 | $40–50 million | not stated |
| combined GAAP R&D, AIPR&D and SG&A expenses | FY2026 | $7.15–7.2 billion | $6.3–6.45 billion |
| combined non-GAAP R&D, AIPR&D and SG&A expenses | FY2026 | approximately $6.0 billion | $5.65–5.75 billion |
| non-GAAP effective tax rate | FY2026 | 19.5%–20.5% (unchanged) | 19.5%–20.5% |
From the release
Revenue: "Total revenues · 3,440.8 · 3,076.4"
Earnings per share: "Net income per diluted common share: · GAAP · $ · 2.56 · $ · 4.20"
total revenue: "Vertex today raised its full year 2026 total revenue guidance to $13.15 billion to $13.25 billion from $13.1 billion to $13.2 billion previously."
PALSONIFY revenue: "PALSONIFY revenue · $40 to $50 million"
combined GAAP R&D, AIPR&D and SG&A expenses: "Combined GAAP R&D, AIPR&D, and SG&A expenses * · $7.15 to $7.2 billion · $6.3 to $6.45 billion"
Quotes are copied from the filing; in table rows, cell borders are shown as “·”.
Key fact: Raised 2026 revenue guidance to $13.15–$13.25 billion; Q3 revenue up 12% to $3.44 billion.
Source
Vertex Pharmaceuticals Incorporated earnings release (SEC filing), accession 0000875320-26-000287, filed 2026-11-02.
Part of the Q3 2026 Guidance Tracker. Educational only, not advice. Free weekly recap every Sunday: yieldterminalpro.com/newsletter.